This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Anti-infective drug developer Replidyne raised $62.5mm with its Series D venture round led by new investors Duquesne Capital Management, HealthCare Investment, and MDS Life Sciences Technology II funds (managed by MDS Capital). Returning backers HealthCare Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings, and Quintiles also participated.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?